Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL

Nature Cell Biology

Volumn 5, Issue 1, 2003, Pages 64-70

  Hergovich, Alexander ^a   Lisztwan, Joanna ^a   Barry, Robert ^a   Ballschmieter, Pia ^a   Krek, Wilhelm ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; MICROTUBULE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEPOLYMERIZATION; DISEASE PREDISPOSITION; GENE DISRUPTION; GENETIC ANALYSIS; HEMANGIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CARCINOMA; MICROTUBULE; NONHUMAN; PATHOGENESIS; PHEOCHROMOCYTOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; VON HIPPEL LINDAU DISEASE;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; GENES, TUMOR SUPPRESSOR; HELA CELLS; HIPPEL-LINDAU DISEASE; HUMANS; KINETICS; LIGASES; MICROSCOPY, FLUORESCENCE; MICROTUBULES; NOCODAZOLE; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

ANIMALIA;

EID: 0037223823     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb899     Document Type: Article

References (38)

1. Kaelin, W. G. Molecular basis of the VIII, hereditary cancer syndrome. Nature Rev. Cancer 2, 673-682 (2002).
2. Iliopoulos O., Ohh, M. & Kaelin, W. G., Jr. pVIII.19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl Acad. Sci. USA 95, 11661-11666 (1998).
3. Blankenship, C., Naglich J. G., Whaley, J. M., Seizinger, B. & Kley, N. Alternative choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity. Oncogene 18, 1529-1535 (1999).
4. Schoenfeld, A., Davidowitz, E. J. & Burk, R. D. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl Acad. Sci. USA 95, 8817-8822 (1998).
5. Gao, J. et al. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene. Cancer Res. 55, 743-747 (1995).
6. Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., Jr. & Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595-10599 (1996).
7. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999).
8. Kamura, T. et al. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci. USA 97, 10430-10435 (2000).
9. Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423-427 (2000).
10. Cockman, M. E. et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733-25741 (2000).
11. Clifford, S. C. et al. Constrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10, 1029-1038 (2001)
12. Hoffman, M. A. et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019-1027 (2001).
13. Lee, S. et al. Nuclear/cytoplasmic localization ofthe von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc. Natl Acad. Sci. USA 93, 1770-1775 (1996).
14. Lee, S. et al. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the Von Hippel-Lindau tumor suppressor protein. Mol. Cell Biol. 19, 1486-1497 (1999).
15. Pause, A. et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable Complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl Acad. Sci. USA 94, 2156- 2161 (1997).
16. Duan, D. R. et al. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl Acad. Sci. USA 92, 6459-6463 (1995).
17. Groulx, I., Bonikalzi, M. E. & Lee, S. Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor proein occurs independently of its assembly with cullin-2. J. Biol. Chem. 275, 8991-9000 (2000).
18. Iliopoulos, O., Kibel, A., Gray, S. & Kaelin, W/G., Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nature Med. 1, 822-826 (1995).
19. Ohh, M. et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1, 959-968 (1998).
20. Shiao, Y. H., Resau, J. H., Nagashima, K., Anderson, L. M. & Ramakrishna, G. The von Hippel-Lindau tumor Suppressor targets to mitochondria. Cancer Res. 60, 2816-2819 (2000).
21. Los, M. et al. Expression pattern of the von Hippel-Lindau protein in human tissuea. Lab. Invest. 75, 231-238 (1996).
22. Corless, C. L., Kibel, A. S., Iliopoulos, O. & Kaelin, W. G., Jr. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum. Pathol. 28, 459-464 (1997).
23. Ye, Y. et al. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int. J. Cancer 78, 62-69 (1998).
24. Schoenfeld, A. R., Davidowitz, E. J. & Burk, R.D. Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region. Int. J. Cancer 91, 457-467 (2001).
25. Lisztwan J., Imbert, G., Wirbelauer, C., Gstaiger, M. & Krek, W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13, 1822-1833 (1999).
26. Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 7, 85-90 (1994).
27. Bradley, J. E., Collins, D. L., Schimke, R. N., Parrot, H. N. & Rothberg, P. G. Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene. Am. J. Med. Genet. 87, 163-167 (1999).
28. Brauch, H. et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum. Genet. 95, 551-556 (1995).
29. Chen, F. et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5, 66-75 (1995).
30. Crossey P. A. et al. Identification of intragenic mutation, in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum. Mol. Genet. 3, 1303-1308 (1994).
31. Zhar, B. et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 8, 348-357 (1996).
32. Eng, C. et al. Mutations in the RET prolo-oncogene and the von Hippel-Lindau disease turnour supressor gene in sporadic and syndromic phaeochromocytomas. J. Med. Genet. 32, 934-937 (1995).
33. Beroud, C. J. D., Gallou, C., Staroz, F., Orfanelli, M.T. & Junien, C. Software and database for the analysis od mutations in the VHL gene. NUcleic Acids Research 26, 256-258 (1998).
34. Brauch, H. et al. VHL alterations in human clear cell renal cell carcinoma: association with advance tumor stage and a novel hot Spot Mutation. Cancer Res. 60, 1942-1948 (2000).
35. Reichardt, P. et al. Recurrent polytopic chromaffin paragangliomas in a 9-year-old boy resulting from a novel germline mutation in the von Hippel-Lidau gene. J. Pediatr. Hematol. Oncol. 24, 145-148 (2002).
36. Groulx, L & Lee, S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear -cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 22, 5319-5336 (2002).
37. cdc2 kinase activation in vertebrates. EMBO J. 10, 3331-3341 (1991).
38. Lisztwan, J. et al. Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of\ the CDC34-SCF pathway. EMBO J. 17, 368-383 (1998).